Tagged with IFPMA,

Coronavirus IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of collaboration being demonstrated as key industry players work towards a common goal.*   Last week, high-level representatives from seven companies…

Coronavirus During a global virtual press briefing on 19 March 2020, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) gathered five global pharmaceutical leaders including Eli Lilly Chairman and CEO David A. Ricks, who is also the president of IFPMA for 2019-2020, to discuss the global ramifications of the COVID-19…

Coronavirus The CEOs and top executives, David Ricks, chairman and CEO, Eli Lilly & Co and IFPMA president, Severin Schwan, CEO, Roche, Paul Stoffels, chief scientific officer, Johnson & Johnson, David Loew, executive VP, Sanofi Pasteur and Rajeev Venkayya, president, Global Vaccines Business Unit, Takeda took part in a virtual press…

IFPMA Earlier this month, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) issued new guidance for the pharmaceutical industry on how it interacts with patients and patient organisations, with the aim of safeguarding patient interests across the world.   When money or resources are involved in interactions, we must at…

Collaboration With sustainable development goals in mind, the global umbrella pharmaceutical association IFPMA has recently launched a platform that fosters collaboration with the aim of tackling problems related to health and equality through partnerships between biopharma companies, governments, academia and other local institutions.    Effective partnerships will help our innovations to…

Diversity Annually, PharmaBoardroom conducts hundreds of interviews with global CEO’s, country managers and industry leaders in the pharma industry. While we have crossed paths with many inspiring females in these positions, out of the top 50 pharma companies, only 3 are headed by women. That is a mere 6% — this…

IFPMA Across the month of January, we at PharmaBoardroom surveyed our executive readership on attitudes towards the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)’s new Code of Practice, effective January 1st, 2019. To download the Code click here and to read our exclusive interview with Melissa Barnes, the IFPMA’s ethics…

IFPMA Eli Lilly and Company’s Melissa Barnes, who chairs the Ethics and Business Integrity Committee (eBIC) at the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), and Thomas Cueni, the organisation’s director general, outline the key features of the IFPMA’s ambitious new Code of Practice and discuss the state of ethics…

IFPMA Last week, the IFPMA released their new Code of Practice with the aim of encouraging complete integrity and ethical responsibility within the pharmaceutical industry. We do not want anything to even potentially suggest that we are trying to get between the healthcare professional and the patient at the time of…

IFPMA On Universal Health Coverage day, the Director General of IFPMA (the International Federation of Pharmaceutical Manufacturers and Associations) explains UHC and how the biopharmaceutical industry is part of the solution.   Our industry is much more than a supplier of medicines and vaccines and is increasingly pioneering new ways to overcome…

IFPMA Geneva, 4 December 2018 – David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly and Company, was elected new President of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for a two-year term. He succeeds Ian C. Read, Chairman of the Board and Chief Executive Officer, Pfizer. The IFPMA…